Glenmark Pharmaceuticals Inc. USA (GLENMARK.NS), Tuesday announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
The bioequivalent and therapeutically equivalent to the reference listed drug, Halaven®2 Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc. will be available in September 2025.
Marc Kikuchi, President & Business Head, North America, said, "As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."
Monday, Glenmark's stock closed at INR 1,918.80, down 0.42 percent on the National Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.